Composition for enhancing exosome delivery efficacy comprising ingenane diterpene

Inzenan diterpene enhances exosome delivery efficacy by weakening intercellular junctions, addressing the inefficiency of therapeutic exosome delivery and improving drug and cosmetic applications.

WO2026235340A1PCT designated stage Publication Date: 2026-11-12HEALIX BIO INC
View PDF 0 Cites 0 Cited by

Patent Information

Application Number
PCT/KR2026/005837
Authority / Receiving Office
WO · WO
Patent Type
Applications
Current Assignee / Owner
Priority Date
2025-05-08
Filing Date
2026-05-06
Publication Date
2026-11-12

AI Technical Summary

Technical Problem

The efficiency of delivering active substances from therapeutic exosomes to cells is low due to collisions and mixing with homeostatic exosomes near the cell membrane, diluting the amount of therapeutic exosomes and inhibiting their contact with the cell membrane.

Method used

Inzenan diterpene is used to weaken intercellular junctions, enhancing the delivery efficacy of cargo-loaded exosomes by promoting their intracellular and tissue delivery.

Benefits of technology

Inzenan diterpene significantly increases the intracellular and tissue delivery of cargo by weakening intercellular junctions, improving drug delivery and cosmetic applications.

✦ Generated by Eureka AI based on patent content.

Smart Images

  • Figure KR2026005837_12112026_PF_FP_ABST
    Figure KR2026005837_12112026_PF_FP_ABST
Patent Text Reader

Abstract

The present invention relates to a novel use of ingenane diterpene and, more specifically, to a use of ingenane diterpene for enhancing exosome delivery efficacy. It was confirmed that the ingenane diterpene according to the present invention weakens intercellular junctions, thereby increasing intracellular / intratissue delivery of cargo loaded in exosomes. Therefore, the ingenane diterpene of the present invention can be variously used in the drug delivery field and the cosmetic field that use exosomes.
Need to check novelty before this filing date? Find Prior Art

Description

Composition for enhancing exosome delivery efficacy containing inzenan diterpene

[0001] The present invention relates to a novel use of inzenan diterpene, and more specifically, to a use of inzenan diterpene to enhance exosome delivery efficacy.

[0002] Extracellular vesicles (EVs) are small spheres derived from cells and surrounded by a phospholipid bilayer that is smaller than a cell, and they exist in all types of body fluids. Extracellular vesicles are a primary means of intercellular communication, containing nucleic acids and proteins which are major components of cells, and have recently garnered attention for their potential as a novel drug delivery method. Advantages that distinguish them significantly from other drug delivery methods include the fact that they are not subject to resistance from an individual's immune system, are not significantly affected by natural barriers such as cell membranes, and can provide selectivity toward specific cells.

[0003] Extracellular vesicles are named in a wide variety of ways depending on the origin of the cell from which they are formed or the method by which they are produced. Based on how they are produced in cells, they are classified into exosomes, microvesicles, ectosomes, microparticles, membrane vesicles, nanovesicles, and outer membrane vesicles. Among extracellular vesicles, exosomes and microvesicles are attracting attention as new means of cargo delivery.

[0004] However, there is a problem in that the efficiency of delivering active substances from therapeutic exosomes to cells is low because these homeostatic exosomes produced and released by cells collide with or mix with therapeutic exosomes loaded with active substances that enter the cell near the cell membrane, thereby relatively diluting the amount of therapeutic exosomes and inhibiting their contact with the cell membrane. Although research on methods to improve the efficiency of introducing these exosomes into cells is emerging, related research results are very scarce.

[0005] Accordingly, the inventors completed the present invention by confirming that inzenan diterpene weakens intercellular junctions and enhances the delivery efficiency of cargo loaded in exosomes.

[0006] Therefore, the objective of the present invention is to provide a composition for enhancing exosome delivery efficacy comprising ingenane diterpene.

[0007] Another objective of the present invention is to provide a kit for enhancing exosome delivery efficacy comprising inzenan diterpene.

[0008] Another objective of the present invention is to provide a composition for reducing cell-to-cell tight junctions comprising inzenan diterpene.

[0009] Another objective of the present invention is to provide a method for enhancing exosome delivery efficacy comprising the step of (a) treating an individual with inzenan diterpene and exosomes.

[0010] Another objective of the present invention is to provide a cosmetic composition for improving skin condition comprising inzenan diterpene and exosomes.

[0011] Another objective of the present invention is to provide a method for improving skin condition comprising the step of administering a composition containing inzenan diterpenes and exosomes to an individual in need thereof.

[0012] To achieve the above objective, the present invention provides a composition for enhancing exosome delivery efficacy comprising inzenan diterpene.

[0013] In addition, the present invention provides a kit for enhancing exosome delivery efficacy comprising inzenan diterpene.

[0014] In addition, the present invention provides a composition for reducing cell-to-cell tight junctions comprising inzenan diterpene.

[0015] In addition, the present invention provides a method for enhancing exosome delivery efficacy comprising the step of (a) treating an individual with inzenan diterpene and exosomes.

[0016] In addition, the present invention provides a cosmetic composition for improving skin condition comprising inzenan diterpene and exosomes.

[0017] In addition, the present invention provides a method for improving skin condition comprising the step of administering a composition containing ingenane diterpene and exosomes to an individual in need thereof.

[0018] It was confirmed that the inzenan diterpene according to the present invention increases the intracellular and tissue delivery of cargo loaded on exosomes by weakening intercellular junctions. Therefore, the inzenan diterpene of the present invention can be utilized in various ways in the fields of drug delivery using exosomes and cosmetic fields.

[0019] Figure 1 shows the results of confirming the cytotoxicity of 20-O-acetyl-ingenol-3-angelate in various human cancer cells.

[0020] Figure 2 shows the results of evaluating the effect of 20-O-acetyl-ingenol-3-angelate on the intracellular delivery of mRNA loaded in exosomes in RAW 264.7 cells.

[0021] Figure 3 shows the results of evaluating the effect of 20-O-acetyl-ingenol-3-angelate on the tissue delivery of mRNA loaded in exosomes in mice.

[0022] Figure 4 shows the results of evaluating the effect of 20-O-acetyl-ingenol-3-angelate on the delivery of mRNA loaded in exosomes into lung tissue in mice.

[0023] Figure 5 shows the results of evaluating the effect of 20-O-acetyl-ingenol-3-angelate on the delivery of mRNA loaded in exosomes into muscle tissue in mice.

[0024] Figure 6 shows the results of confirming the effect of 20-O-acetyl-ingenol-3-angelate on intercellular junctions in HCT15 cells.

[0025] The present invention will be described in detail below.

[0026] According to an embodiment of the present invention, the present invention provides a composition for enhancing exosome delivery efficacy comprising inzenan diterpene. The present invention also provides a kit for enhancing exosome delivery efficacy comprising inzenan diterpene.

[0027] In a specific embodiment of the present invention, the ingenan diterpene may be one or more selected from the group consisting of ingenol-3-angelate, ingenol-5,20-diacetate, ingenol-3,5,20-triacetate, ingenol-20-acetate, and 20-O-acetyl-ingenol-3-angelate (OAIA), and preferably may be 20-O-acetyl-ingenol-3-angelate.

[0028] In a specific embodiment of the present invention, the exosome is preferably a plant or animal-derived exosome, but the scope of the present invention is not limited thereto.

[0029] In a specific embodiment of the present invention, it is preferable that the inzenan diterpene promotes the absorption of exosomes by cells or tissues.

[0030] In a specific embodiment of the present invention, the composition is preferably intended for treatment of a target cell or tissue site. The composition of the present invention may pre-treat a target cell or tissue site to which exosomes are to be delivered; and / or simultaneously treat with exosomes. In this case, the intercellular junctions of the exosomes-treated cells and tissues can be weakened to enhance the intracellular and intratissue delivery efficiency of the cargo loaded on the exosomes. At this time, the treatment of the cell or tissue site may be applied in various ways depending on the type of target cell or tissue, and may be performed by intramuscular injection, skin application, or lung spray.

[0031] In a specific embodiment of the present invention, it is preferable that the inzenan diterpene weakens the intercellular junction. That is, the inzenan diterpene can weaken the intercellular junction to improve the efficiency of intracellular and tissue delivery of the cargo loaded in the exosome.

[0032] In a specific embodiment of the present invention, it is preferable that the exosome is loaded with a cargo. The cargo may be various substances loaded on the exosome for the diagnosis or treatment of diseases, health promotion, cosmetic purposes, etc. For example, the cargo may be one or more selected from the group consisting of proteins, nucleic acids, peptides, lipids, glycolipids, minerals, sugars, nanoparticles, biological agents, contrast agents, drugs, and compounds. In addition, the cargo may be a drug for the prevention, improvement, or treatment of specific diseases, and its type is not limited.

[0033] Examples of the above contrast material may be fluorescent materials, and the fluorescent material may be fluorescent proteins, molecules that emit light in an excited state, metal ions, complex compounds, organic dyes, conductors, semiconductors, insulators, quantum dots, quantum wires, etc., but the types are not limited.

[0034] Examples of the above fluorescent proteins include EGFP (enhanced green fluorescent protein), ECFP (enhanced cyan fluorescent protein), EBFP (enhanced blue fluorescent protein), EYFP (enhanced yellow fluorescent protein), and RFP (red fluorescent protein).

[0035] In addition, examples of the above fluorescent materials include pyrene or its derivatives, the cyanine (Cy) series, the Alexa Fluor series, the BODIPY series, the DY series, rhodamine or its derivatives, fluorescein or its derivatives, coumarin or its derivatives, acridine homodimer or its derivatives, acridine orange or its derivatives, 7-aminoactinomycin D (7-AAD) or its derivatives, actinomycin D or its derivatives, ACMA (9-amino-6-chloro-2-methoxyacridine) or its derivatives, DAPI or its derivatives, dihydroethidium or Its derivatives, ethidium bromide or its derivatives, ethidium homodimer-1 (EthD-1) or its derivatives, ethidium homodimer-2 (EthD-2) or its derivatives, ethidium monoazide or its derivatives, hexidium iodide or its derivatives, bisbenzimide (Hoechst 33258) or its derivatives, Hoechst 33342 or its derivatives, Hoechst 34580 or its derivatives, hydroxystilbamidine or its derivatives, LDS 751 or its derivatives, propidium Propidium Iodide (PI) or its derivatives, Calcein or its derivatives, Oregon Green or its derivatives,Examples include Magnesium Green or its derivatives, Calcium Green or its derivatives, JOE or its derivatives, Tetramethylrhodamine or its derivatives, TRITC or its derivatives, Tamra (N,N,N',N'-tetramethyl-6-carboxyrhodamine, TAMRA) or its derivatives, Pyronin Y or its derivatives, Lissamine or its derivatives, ROX or its derivatives, Calcium Crimson or its derivatives, Texas Red or its derivatives, Nile Red or its derivatives, Thiadicarbocyanine or its derivatives, Dansylamide or its derivatives, Cascade Blue, DAPI (4',6-diamidino-2-phenylindole), etc.

[0036] The composition and kit of the present invention may further include additional components for the preservation and maintenance of exosomes.

[0037] To monitor the delivery of exosomes, the kit may include tools, reagents, etc. commonly used in the art for immunological analysis. Examples of such tools or reagents include, but are not limited to, suitable carriers, labeling substances capable of generating detectable signals, chromophores, solvents, detergents, buffers, stabilizers, etc. If the labeling substance is an enzyme, it may include a substrate capable of measuring enzyme activity and a reaction stopper. The carrier may be a soluble carrier or an insoluble carrier. An example of a soluble carrier is a physiologically acceptable buffer known in the art, e.g., PBS. Examples of insoluble carriers may include polymers such as polystyrene, polyethylene, polypropylene, polyester, polyacrylonitrile, fluoropolymer, cross-linked dextran, polysaccharide, and latex plated with metal, as well as other paper, glass, metal, agarose, and combinations thereof.

[0038] Since the kit of the present invention comprises the composition described above, redundant details are omitted to avoid excessive complexity in this specification.

[0039]

[0040] According to another aspect of the present invention, the present invention provides a composition for reducing cell-to-cell tight junctions comprising inzenan diterpene.

[0041] The composition of the present invention can enhance drug delivery by reducing cell-to-cell tight junctions in various cells. For example, when the composition of the present invention is treated together with exosomes, the intracellular and tissue delivery of useful substances and loaded cargo inside the exosomes can be enhanced.

[0042] The composition of the present invention may pre-treat a target cell or tissue site; and / or simultaneously treat with exosomes.

[0043]

[0044] According to another aspect of the present invention, the present invention provides a method for enhancing exosome delivery efficacy comprising the step of (a) treating an individual with inzenan diterpene and exosomes.

[0045] The above-mentioned entity may be an entity to which exosomes are to be delivered, and more specifically, may be a cell or tissue of the entity. Methods for delivering exosomes to the above-mentioned entity may be applied in various ways depending on the type of target cell and tissue, and may be administered via intramuscular injection, skin application, or lung spray.

[0046] In a specific embodiment of the present invention, the method may pre-treat the individual with the inzenan diterpene before exosome treatment; treat simultaneously with the exosome; or pre-treat the individual before exosome administration and then treat simultaneously with the exosome.

[0047] In an embodiment of the present invention, it was confirmed that the intracellular and tissue delivery of Cargo is significantly enhanced when the individual is pretreated with inzenan diterpene before exosome treatment; simultaneously treated with exosomes; or pretreated with exosomes after being pretreated before exosome administration. Preferably, the pretreatment is performed for 1 to 24 hours, and more preferably for 2 to 5 hours.

[0048]

[0049] According to another aspect of the present invention, the present invention provides a cosmetic composition for improving skin condition comprising inzenan diterpene and exosomes.

[0050] The inzenan diterpene of the present invention can temporarily relax skin cell-cell junctions when treated with skin cells, thereby enabling the smooth delivery of skin condition improvement substances, such as exosomes, or cargo contained in exosomes, into the skin cells.

[0051] In particular, exosomes are known to have excellent skin condition improvement effects in this field. Accordingly, when the cosmetic composition of the present invention includes inzenan diterpene and exosomes, the efficiency of intracellular and tissue delivery of exosomes can be enhanced, which can further increase the skin condition improvement effect of the cosmetic composition.

[0052] In a specific embodiment of the present invention, the improvement of the skin condition may be enhancement of skin elasticity, anti-wrinkle, moisturization, whitening, skin soothing, skin regeneration, pore reduction, reduction of sebum secretion, or improvement of acne, and the scope of the present invention is not limited thereto.

[0053] The above-mentioned Cargo may be a known substance that exhibits efficacy in improving skin condition.

[0054] When the composition of the present invention is a cosmetic, in addition to the exosomes loaded with the inzenan diterpene and Cargo, it may include conventional cosmetic base ingredients, such as, for example, conventional emulsifiers such as stabilizers, solubilizers, pigments and fragrances, and carriers. Furthermore, the cosmetic may be manufactured in any formulation conventionally produced in the art and, although not specifically limited, may have formulations such as toners, essences, lotions, pastes, surfactant-containing cleansers, creams, packs, gels, ointments, powders, patches, or sprays.

[0055] In the case where the formulation of the above cosmetic composition is a paste, cream, or gel, one or more selected from the group consisting of animal oil, vegetable oil, wax, paraffin, starch, tracanth, cellulose derivative, polyethylene glycol, silicone, bentonite, silica, talc, and zinc oxide may be used as carrier components, and in the case where the formulation is a lotion or essence, a solvent, a solubilizing agent, or an emulsifying agent may be used as carrier components, for example, one or more selected from the group consisting of water, ethanol, isopropanol, ethyl carbonate, ethyl acetate, benzyl alcohol, benzyl benzoate, propylene glycol, 1,3-butylene glycol, oil, glycerol aliphatic ester, polyethylene glycol, and fatty acid ester of sorbitan may be used.

[0056] In addition, if the formulation of the cosmetic composition is a powder or a spray, one or more selected from the group consisting of lactose, talc, silica, aluminum hydroxide, calcium silicate, and polyamide powder may be used as carrier components, and in particular, if it is a spray, it may additionally include a propellant such as chlorofluorohydrocarbon, propane / butane, or dimethyl ether. In addition, if the formulation of the cosmetic composition is a surfactant-containing cleansing agent, one or more selected from the group consisting of aliphatic alcohol sulfate, aliphatic alcohol ether sulfate, sulfosuccinic acid monoester, isethionate, imidazolinium derivative, methyl taurate, sarcosinate, fatty acid amide ether sulfate, alkylamidobetaine, aliphatic alcohol, fatty acid glyceride, fatty acid diethanolamide, vegetable oil, lanolin derivative, and ethoxylated glycerol fatty acid ester may be used as carrier components.

[0057]

[0058] According to another aspect of the present invention, the present invention provides a method for improving skin condition comprising the step of administering a composition comprising inzenan diterpene and exosomes to an individual in need thereof.

[0059] In a specific embodiment of the present invention, the individual may be an individual requiring improvement of the skin condition, and more specifically, may be an individual requiring effects such as skin elasticity enhancement, anti-wrinkle, moisturization, whitening, skin soothing, skin regeneration, pore reduction, reduction of sebum secretion, or improvement of acne, but is not limited thereto.

[0060] In a specific embodiment of the present invention, the composition may be in the form of a cosmetic composition, a quasi-drug composition, or a pharmaceutical composition, but is not limited thereto. The cosmetic composition may be provided in various formulations such as skin, toner, essence, serum, ampoule, lotion, cream, gel, oil, mist, patch, or mask pack, and may additionally include emulsifiers, moisturizers, thickeners, stabilizers, antioxidants, fragrances, colorants, and preservatives used in conventional cosmetic compositions. The quasi-drug composition may be provided in external formulations such as ointments, creams, gels, lotions, sprays, or patches for skin protection or improvement. The pharmaceutical composition may include a pharmaceutically acceptable carrier, and the carrier may include physiological saline, a buffer solution, a solvent, a dispersant, or a stabilizer. The pharmaceutical composition may be applied in a parenteral form including external application to the skin, but is not limited thereto.

[0061]

[0062] Redundant content is omitted out of consideration for the complexity of this specification, and terms not otherwise defined in this specification have the meanings commonly used in the technical field to which this invention belongs.

[0063] The present invention will be described in more detail below through examples. These examples are solely for illustrating the present invention, and it will be obvious to those skilled in the art that the scope of the present invention is not to be interpreted as being limited by these examples.

[0064]

[0065] [Experimental Example]

[0066] Experimental Example 1. Cell line and mouse

[0067] Mouse macrophage RAW264.7 cells and various human cancer cells (THP-1, MRC-5, HCT-8, HCT15, HCT116, PANC1, PC3) were purchased from ATCC (American Type Culture Collection, Manassas, VA, USA).

[0068] Male C57BL / 6 mice aged 7-8 weeks (average weight 23g) were used for the experiment, and the experiment was performed in accordance with animal experiment guidelines (Pusan ​​National University Animal Experiment Permit No. PNU-2023-0389).

[0069]

[0070] Experimental Example 2. Reagents

[0071] The ingenane diterpene 20-O-acetyl-ingenol-3-angelate (OAIA (CID 14136933)) was purchased from Biorbyt (Cambridge, UK). Additionally, the Phospho-PKC sampler antibody kit was purchased from Cell Signaling Technology.

[0072]

[0073] The positive control group used vincristine, an anticancer drug that induces cytotoxicity by causing apoptosis. Additionally, the negative control group used a dopamine receptor agonist, which is presumed to be non-cytotoxic.

[0074]

[0075] Experimental Example 3. Animal and plant exosome prep and Western blotting

[0076] Animal exosomes were isolated by mixing the cell culture supernatant with total Exosome Isolation Reagent (Invitrogen #4478359) and ultracentrifuging (100,000 g). Animal exosomes were identified by Western blotting using CD63 and TSG101 antibodies (Thermo Fisher, Waltham, MA, USA).

[0077]

[0078] Plant exosomes were isolated from the *Cucumis sativus* var. sativus. Specifically, the *Cucumis sativus* cucumber was crushed and filtered, then centrifuged in the 1,000-10,000 g range to obtain a supernatant containing exosomes. 6 ml of the supernatant was subjected to sucrose concentration gradient ultracentrifugation (150,000 g) to isolate the plant exosomes in a pure form. The size and quantity of the isolated plant exosomes were evaluated using an NTA instrument.

[0079] As a result, the production of plant exosomes is 2x10 8 It is particle / ml, and 2x10 for the experiments described below 6 Used in particles.

[0080]

[0081] Experimental Example 4. Production of mRNA-loaded exosomes

[0082] After cloning the NanoLuciferase gene and RFP gene into the pT7ET-1 vector (Clontech), respectively, PCR was performed using primers containing a T7 promoter and a T7 terminator. In vitro transcription was performed using the PCR products as templates. In vitro transcription was carried out using HiScribe. ® The T7 High Yield RNA Synthesis Kit (NEB, Boston, MA, USA) and CleanCap mRNA Capping Technology (TriLink Biotechnologies, San Diego, CA, USA) were used, and the procedure was performed according to the manufacturer's manual. After measuring the amount of in vitro transcript using a nanodrop, 1 mg of mRNA was loaded into the plant exosomes or animal exosomes prepared in Experimental Example 1.

[0083]

[0084] Experimental Example 5. Nanoluciferase assay and RFP imaging

[0085] Exosomes loaded with 0.25 mg of nanoluciferase mRNA were added to the cell culture medium. After 24 hours of treatment, cell lysates were obtained, and absorbance was measured using a nanoluciferase assay kit (Promega, Madison, WI, USA).

[0086]

[0087] Exosomes loaded with 1 mg of nanoluciferase mRNA were administered to the lungs and hind leg muscles of mice. After 24 hours of administration, the tissues were isolated and lysed, and absorbance was measured using a nanoluciferase assay kit (Promega, Madison, WI, USA). Exosomes were also administered to mice or hind leg muscles in the same manner. After 24 hours of administration, images were analyzed using a VISQUE InVivo Smart-LF imaging instrument (Vieworks, Anyang, Korea).

[0088]

[0089] Experimental Example 6. MTT assay

[0090] The MTT assay kit was purchased from Thermo Fisher, and the analysis was performed according to the manufacturer's manual.

[0091]

[0092] Experimental Example 7. Fluorescent staining

[0093] Pores were created in the cell membranes of cells using Triton X-100, and specific proteins were stained using ZO-1 Alexa Fluor® 488 (sc-33725), E cadherin Alexa Fluor® 488 (sc-21791), and Calnexin Alexa Fluor® 488 (sc-23954; Santa Cruz Biotech; SC-374015) antibodies. For F-actin, the F-actin antibody (MA1-80729; Invitrogen) was used to bind to the antigen first, followed by red staining using IgG-Alexa Fluor® 647 (# A55749; Thermo Fisher) as a secondary antibody. After antibody treatment and cell washing, cells were fixed and nuclei were stained using VECTASHIELD® Antifade Mounting Medium with DAPI (H-1200-10; Vector Laboratories, Newark, CA, USA).

[0094]

[0095] [Example]

[0096] Example 1. Confirmation of cytotoxicity of OAIA

[0097] To confirm the cytotoxicity of OAIA, various human cancer cells (THP-1, MRC-5, HCT-8, HCT15, HCT116, PANC1, PC3) were prepared. The prepared cells were treated with OAIA at various concentrations (1-10 mM) and cultured for 16 hours. The control group was treated with the anticancer drug vincristine and a dopamine receptor agonist. After culture, an MTT assay was performed to measure the metabolic activity of live cells, and the results are shown in Figure 1.

[0098] As shown in Figure 1, the positive control (anti-cancer drug) exhibited strong cytotoxicity at concentrations of 1 μM or less. Additionally, the negative control (dopamine receptor agonist) showed relatively low cytotoxicity in HCT-8 and HCT116 cells, but exhibited cytotoxicity similar to the positive control in HCT15, PANC1, and PC3 cells. In contrast, the OAIA-treated group was found to have very low cytotoxicity compared to the positive and negative controls.

[0099]

[0100] Example 2. Evaluation of the effect of OAIA on the intracellular delivery of mRNA loaded onto exosomes

[0101] In this example, the effect of OAIA on the intracellular delivery of mRNA loaded onto exosomes was evaluated. Specifically, plant exosomes (OE exosome, 2x10⁶) extracted from *Baekdadagi* cucumbers were used. 6 nanoluc mRNA (0.25 mg) was loaded onto a particle. RAW 264.7 cells were treated with OAIA (1 μM), exosomes (2.5 μl / well), and nanoluc mRNA (0.25 μg / well), and the specific experimental groups are as follows.

[0102]

[0103] - nanoluc mRNA treatment group

[0104] - Treatment group for exosomes loaded with nanoluc mRNA

[0105] - Exosome-treated groups loaded with nanoluc mRNA after OAIA 2, 5, and 22 hours of pretreatment

[0106] - Group treated simultaneously with exosomes loaded with OAIA and nanoluc mRNA

[0107]

[0108] After treating the cells as described above, they were cultured for 24 hours. After culture, the cells were lysed, and a nanoluciferase assay was performed using the obtained cell lysates. The results of the nanoluciferase assay are shown in Figure 2.

[0109] As shown in Figure 2, nanoluc mRNA itself is hardly delivered (1st column), but it was confirmed that nanoluc mRNA is delivered to RAW 264.7 cells when loaded into exosomes (2nd column).

[0110] When pretreated with OAIA for 22 hours, nanoluc mRNA delivery increased slightly (3rd column), but when pretreated for 5 or 2 hours, nanoluc mRNA delivery was significantly increased (4th and 5th columns). In addition, when OAIA and nanoluc-loaded exosomes were treated simultaneously, nanoluc mRNA delivery was significantly increased compared to the untreated OAIA group (6th column).

[0111]

[0112] In addition, the same experiment was performed using animal exosomes isolated from RAW 264.7 cells.

[0113] As a result, it was confirmed that the delivery of nanoluc mRNA was significantly increased when exosomes loaded with nanoluc mRNA were treated after OAIA pretreatment, or when OAIA and exosomes were treated simultaneously.

[0114]

[0115] The above results indicate that OAIA promotes the absorption of exosomes by cells, and consequently, the delivery of mRNA loaded in exosomes is significantly increased.

[0116]

[0117] Example 3. Evaluation of the effect of OAIA on the delivery of exosome-loaded mRNA into mouse tissues

[0118] In this example, the effect of OAIA on the delivery of mRNA loaded onto exosomes into mouse tissues was evaluated. Specifically, plant exosomes (OE exosome, 2x10⁶) extracted from *Baekdadagi* cucumbers were used. 6 nanoluc mRNA (0.25 mg) was loaded onto particles. The lungs of 7-8 week old mice (n=2) were pretreated with OAIA (2 mg) or PBS for 16 hours. Exosomes loaded with nanoluc mRNA were injected into the lungs of the mice, either alone or mixed with OAIA (1 mg). For muscle samples, hind leg muscles were used, and exosomes loaded with nanoluc mRNA were injected intramuscularly either alone or mixed with OAIA (2 mg). 24 hours after administration, lungs and hind leg muscles were isolated from the mice, and the tissues were lysed. A nanoluciferase assay was performed using the tissue lysates, and the results are shown in Figure 3.

[0119] As shown in Figure 3, it was confirmed that the delivery of loaded mRNA was significantly increased in the lungs and hind leg muscles when exosomes loaded with nanoluc mRNA were treated in combination with OAIA. The above results indicate that OAIA promotes the uptake of exosomes into tissues in animals, and consequently, the delivery of mRNA loaded in exosomes is significantly increased.

[0120] .

[0121] Example 4. Evaluation of the effect of OAIA on the delivery of exosome-loaded mRNA into mouse lung tissue.

[0122] Plant exosomes (OE exosome, 2x10⁻¹⁰) extracted from *Baekdadagi* cucumber 6nanoluc mRNA (0.25 mg) was loaded onto exosomes. The lungs of 7-8 week old mice (n=3) were pretreated with OAIA (2 mg) for 3 hours. After pretreatment, exosomes loaded with nanoluc mRNA and OAIA were injected into the lung tissue. Lung tissue was obtained 24 hours after exosome treatment and lysed. A nanoluciferase assay was performed using the tissue lysate, and the results are shown in Figure 4.

[0123] As shown in Figure 4, it was confirmed that the delivery of mRNA into lung tissue was significantly increased in the group treated with exosomes loaded with nanoluc mRNA in combination with OAIA (Exo RNA / OAIA) compared to the group treated with nanoluc mRNA alone (Exo RNA).

[0124]

[0125] Example 5. Evaluation of the effect of OAIA on the delivery of exosome-loaded mRNA into mouse muscles

[0126] Plant exosomes (OE exosome, 2x10⁻¹⁰) extracted from *Baekdadagi* cucumber 6 RFP mRNA (0.25 mg) was loaded onto a particle. Exosomes loaded with RFP mRNA and OAIA (2 mg) were intramuscularly injected into the hind muscles of 7-8 week old mice (n=3). RFP expression was evaluated via imaging analysis 24 hours after injection. The results of the imaging analysis are shown in Figure 5.

[0127] As shown in Figure 5, it was confirmed that the expression of RFP mRNA in the muscle was increased in the exosome-treated group loaded with RFP mRNA (Exosome) compared to the RFP mRNA-treated group (con). In addition, it was confirmed that the expression of mRNA in the muscle was significantly increased in the exosome-treated group loaded with RFP mRNA and the OAIA combined treatment group (Exosome+OAIA) compared to the exosome-treated group loaded with RFP mRNA (Exosome).

[0128]

[0129] Example 6. Confirmation of the effect of OAIA on intercellular junctions

[0130] ZO-1 (Zonula Occludens-1) is a scaffolding protein that plays an important role in the formation, maintenance, and regulation of tight junctions between epithelial and endothelial cells. E-cadherin mediates calcium-dependent intercellular adhesion, and calnexin affects the stability and function of adhesion molecules such as integrins and cadherins.

[0131] Accordingly, in this embodiment, the effect of OAIA on the expression of intercellular junction-related proteins in human colorectal cancer cells, HCT15, was confirmed through fluorescent staining. After treating prepared HCT15 cells with 1 μM of OAIA, intracellular ZO-1, E-cadherin, and calnexin were fluorescently stained. ZO-1, E-cadherin, and calnexin were stained green, while F-actin was stained red. The fluorescently stained cells were observed under a microscope, and the results are shown in Figure 6.

[0132] As shown in Figure 6, it was confirmed that OAIA weakens intercellular junctions (green-stained areas) in human colorectal cancer cell line HCT15 cells.

[0133]

[0134] In summary, the inventors have confirmed that 20-O-acetyl-ingenol-3-angelate increases exosome delivery efficacy. More specifically, the inventors have confirmed that the intracellular and tissue delivery of the cargo is significantly enhanced when the 20-O-acetyl-ingenol-3-angelate is (i) co-treated with exosomes loaded with cargo; or (i) co-treated with exosomes loaded with cargo after pretreatment. Furthermore, through additional experiments, the mechanism by which 20-O-acetyl-ingenol-3-angelate increases the intracellular and tissue delivery of the cargo loaded on exosomes by weakening intercellular junctions was confirmed. Therefore, the 20-O-acetyl-ingenol-3-angelate of the present invention can be utilized in various ways in the fields of drug delivery using exosomes and cosmetic applications.

[0135]

[0136] Foregoing, specific parts of the present invention have been described in detail. It will be apparent to those skilled in the art that such specific descriptions are merely preferred embodiments and do not limit the scope of the invention. Accordingly, the actual scope of the invention is defined by the appended claims and their equivalents.

Claims

1. A composition for enhancing exosome delivery efficacy comprising ingenane diterpene.

2. In Paragraph 1, A composition wherein the above-mentioned ingenol diterpene is one or more selected from the group consisting of ingenol-3-angelate, ingenol-5,20-diacetate, ingenol-3,5,20-triacetate, ingenol-20-acetate, and 20-O-acetyl-ingenol-3-angelate (OAIA).

3. A composition according to claim 1, wherein the exosome is a plant or animal-derived exosome.

4. A composition according to claim 1, wherein the inzenan diterpene promotes exosome absorption by cells or tissues.

5. The composition of claim 1, wherein the composition is for treating target cells or tissue sites.

6. A composition according to claim 1, wherein the inzenan diterpene weakens intercellular junctions.

7. A composition according to claim 1, wherein the exosome is loaded with cargo.

8. A composition according to claim 7, wherein the said cargo is one or more selected from the group consisting of proteins, nucleic acids, peptides, lipids, glycolipids, minerals, sugars, nanoparticles, biological agents, contrast agents, drugs, and compounds.

9. Kit for enhancing exosome delivery efficacy containing inzenan diterpene.

10. A composition for reducing cell-to-cell tight junctions comprising ingenane diterpene.

11. (a) a step of treating an individual with inzenan diterpene and exosomes; a method for enhancing exosome delivery efficacy comprising.

12. A method according to claim 11, wherein the inzenan diterpene is pretreated in an individual prior to exosome treatment; treated simultaneously with exosomes; or pretreated in an individual prior to exosome administration and then treated simultaneously with exosomes.

13. A cosmetic composition for improving skin condition comprising inzenan diterpenes and exosomes.

14. A cosmetic composition for improving skin condition according to claim 13, wherein the skin condition improvement is enhancement of skin elasticity, anti-wrinkle, moisturizing, whitening, skin soothing, skin regeneration, pore reduction, reduction of sebum secretion, or improvement of acne.

15. A method for improving skin condition comprising the step of administering a composition containing ingenane diterpene and exosomes to an individual in need thereof.